MX2019009860A - Uso mejorado de neurotoxina botulinica en el tratamiento de sialorrea. - Google Patents

Uso mejorado de neurotoxina botulinica en el tratamiento de sialorrea.

Info

Publication number
MX2019009860A
MX2019009860A MX2019009860A MX2019009860A MX2019009860A MX 2019009860 A MX2019009860 A MX 2019009860A MX 2019009860 A MX2019009860 A MX 2019009860A MX 2019009860 A MX2019009860 A MX 2019009860A MX 2019009860 A MX2019009860 A MX 2019009860A
Authority
MX
Mexico
Prior art keywords
sialorrhea
treatment
botulinum neurotoxin
improved use
botulinum neurotoxins
Prior art date
Application number
MX2019009860A
Other languages
English (en)
Inventor
Csikos Janos
Althaus Michael
Pulte Irena
Krüer Markus
Wegener Nico
Original Assignee
Merz Pharma Gmbh & Co Kgaa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merz Pharma Gmbh & Co Kgaa filed Critical Merz Pharma Gmbh & Co Kgaa
Publication of MX2019009860A publication Critical patent/MX2019009860A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a usos mejorados de neurotoxinas botulínicas en el tratamiento de la sialorrea o enfermedades o afecciones relacionadas con el aumento de la producción de saliva. En particular, se divulgan neurotoxinas botulínicas que se administran en glándulas parótidas y submandibulares en una relación de dosis de 1.45 a 1 y 1.7 a 1.
MX2019009860A 2017-03-24 2018-03-19 Uso mejorado de neurotoxina botulinica en el tratamiento de sialorrea. MX2019009860A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17162719 2017-03-24
PCT/EP2018/056850 WO2018172264A1 (en) 2017-03-24 2018-03-19 Improved use of botulinum neurotoxin in the treatment of sialorrhea

Publications (1)

Publication Number Publication Date
MX2019009860A true MX2019009860A (es) 2019-10-15

Family

ID=58412969

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019009860A MX2019009860A (es) 2017-03-24 2018-03-19 Uso mejorado de neurotoxina botulinica en el tratamiento de sialorrea.

Country Status (12)

Country Link
US (3) US10709772B2 (es)
EP (1) EP3600384A1 (es)
JP (2) JP7007392B2 (es)
KR (1) KR20190126794A (es)
CN (1) CN110430892A (es)
AU (1) AU2018237799A1 (es)
BR (1) BR112019016585A2 (es)
CA (1) CA3051785A1 (es)
IL (2) IL304733B1 (es)
MX (1) MX2019009860A (es)
WO (1) WO2018172264A1 (es)
ZA (1) ZA201904752B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201607901D0 (en) * 2016-05-05 2016-06-22 Ipsen Biopharm Ltd Chimeric neurotoxins
MX2019009860A (es) * 2017-03-24 2019-10-15 Merz Pharma Gmbh & Co Kgaa Uso mejorado de neurotoxina botulinica en el tratamiento de sialorrea.
EP3752128A1 (de) * 2018-02-16 2020-12-23 Bontana Therapies Gmbh Nukleinsäure-basiertes botulinum neurotoxin zur therapeutischen anwendung
US10960061B1 (en) * 2019-10-18 2021-03-30 Penland Foundation Treatment of amyotrophic lateral sclerosis using botulinum toxin
US10967052B1 (en) 2019-10-18 2021-04-06 Penland Foundation Treatment of dyslexia using botulinum toxin
US11925677B2 (en) 2021-07-12 2024-03-12 Penland Foundation Treatment of diabetes and chronic pancreatitis using botulinum toxin
US11738071B2 (en) 2021-07-12 2023-08-29 Penland Foundation Treatment of acute and chronic kidney disease

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19925739A1 (de) 1999-06-07 2000-12-21 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum mit einem Botulinum-Neurotoxin
DE10333317A1 (de) 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
CA2578250C (en) 2004-07-26 2013-03-05 Merz Pharma Gmbh & Co. Kgaa Therapeutic composition with a botulinum neurotoxin
US20090142430A1 (en) * 2007-12-04 2009-06-04 Ira Sanders Methods for Preventing or Treating Complications of Airway Control Devices
HUE046037T2 (hu) 2008-03-14 2020-01-28 Allergan Inc Immun-alapú, A szerotípusú botulinum toxin aktivitás vizsgálati eljárások
WO2010013494A1 (ja) * 2008-07-31 2010-02-04 財団法人化学及血清療法研究所 軸索輸送されないボツリヌス神経毒素製剤を含有する医薬組成物およびその利用
SI2761065T1 (en) 2011-09-29 2018-02-28 Cellsnap, Llc Ingredients and procedures for toxicity testing
US20180360995A1 (en) * 2012-04-02 2018-12-20 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
KR20140147950A (ko) 2013-06-20 2014-12-31 서울대학교산학협력단 필러와 보틀리눔 독소를 포함하는 피부 주름, 노화 개선 또는 신경근육 관련 질환 치료용 조성물
SG11201510685UA (en) 2013-06-28 2016-01-28 Merz Pharma Gmbh & Co Kgaa Means and methods for the determination of the biological activity of neurotoxin polypeptides in cells
US9480731B2 (en) * 2013-12-12 2016-11-01 Medy-Tox, Inc. Long lasting effect of new botulinum toxin formulations
SG11201705019PA (en) * 2014-12-23 2017-07-28 Merz Pharma Gmbh & Co Kgaa Botulinum toxin prefilled container
MX2019009860A (es) * 2017-03-24 2019-10-15 Merz Pharma Gmbh & Co Kgaa Uso mejorado de neurotoxina botulinica en el tratamiento de sialorrea.

Also Published As

Publication number Publication date
US20200297823A1 (en) 2020-09-24
RU2019123259A (ru) 2021-04-26
IL268688B2 (en) 2024-01-01
JP2022058511A (ja) 2022-04-12
US20230270829A1 (en) 2023-08-31
BR112019016585A2 (pt) 2020-03-31
US20190000938A1 (en) 2019-01-03
AU2018237799A1 (en) 2019-08-08
ZA201904752B (en) 2020-02-26
US11529398B2 (en) 2022-12-20
EP3600384A1 (en) 2020-02-05
JP2020511428A (ja) 2020-04-16
JP7495438B2 (ja) 2024-06-04
IL268688A (en) 2019-10-31
IL304733A (en) 2023-09-01
KR20190126794A (ko) 2019-11-12
CA3051785A1 (en) 2018-09-27
RU2019123259A3 (es) 2021-06-24
US10709772B2 (en) 2020-07-14
WO2018172264A1 (en) 2018-09-27
JP7007392B2 (ja) 2022-01-24
IL304733B1 (en) 2024-04-01
CN110430892A (zh) 2019-11-08
IL268688B1 (en) 2023-09-01

Similar Documents

Publication Publication Date Title
MX2019009860A (es) Uso mejorado de neurotoxina botulinica en el tratamiento de sialorrea.
PH12019501414A1 (en) Amino acid compositions and methods for the treatment of liver diseases
ZA201705114B (en) Cysteine protease
MY188696A (en) Cysteine protease
WO2018229236A3 (en) COMPOSITIONS COMPRISING BACTERIAL STRAINS
PH12015501983B1 (en) Peptides and compositions for treatment of joint damage
MX2021006714A (es) Neurotoxinas cationicas.
WO2016081834A3 (en) Therapeutic variant alpha-2-macroglobulin compositions
WO2016112208A3 (en) Topical applications of kv1.3 channel blocking peptides to treat skin inflammation
MX2019001634A (es) Compuestos amidas, composiciones farmacéuticas de estos y métodos para utilizarlos.
MX2022010186A (es) Neurotoxinas botulinas para uso en terapia.
MX2019003970A (es) Péptidos de arginasa inmunogénicos.
IL285634A (en) New uses of the botulinum neurotoxin to treat tremors
MX2018005352A (es) Metodos y composiciones para el tratamiento de amiloidosis.
MY194448A (en) Short synthetic peptide for treating diseases and/or conditions related to angiogenesis
ZA202105101B (en) Peptides for treatment and prevention of diabetes and associated disorders
MX2020009566A (es) Compuestos como moduladores de la se?alizacion de tlr2.
EA202092045A1 (ru) Лечение и предупреждение преэклампсии
WO2019036725A3 (en) PEPTIDE INHIBITORS OF TAU AGGREGATION
MX2018015080A (es) Produccion de neurotoxinas clostridiales activadas.
MX2019000006A (es) Composiciones para el tratamiento de estrias y ulceras de origen isquemico.
MX2021001361A (es) Composicion liquida de fibrinogeno humano.
PH12017501918A1 (en) Multi-peptide composition
BR112018012343A2 (pt) composições de benzofenonas poli-hidroxiladas e métodos de tratamento de distúrbios neurodegenerativos
MX2020009877A (es) Péptidos neutralizantes de miotoxina.